Author: Anna Smith

Imfinzi cancer combo falls short in DANUBE trial

Despite the setback, AstraZeneca says that it “remains committed to addressing unmet needs in bladder cancer.”

Post-surgery chemo halves risk of recurring rare kidney cancer

71% of patients given chemotherapy survived for three years or more after joining the trial without their disease coming back, compared with 46% of patients who were on surveillance.

NICE pushes Doptelet for pre-surgery liver disease treatment

Last year, the therapy received a positive opinion from the EMA’s CHMP.

Sanofi, Babylon link-up to tackle digestive health

Only an estimated 30% of people in the UK who suffer from IBS have actually been diagnosed and, of those, 61% often mistreat their symptoms with analgesics or antacids.